Armistice Capital, LLC Neurocrine Biosciences Inc Transaction History
Armistice Capital, LLC
- $7.08 Billion
- Q4 2024
A detailed history of Armistice Capital, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 892,000 shares of NBIX stock, worth $101 Million. This represents 1.72% of its overall portfolio holdings.
Number of Shares
892,000
Previous 181,381
391.78%
Holding current value
$101 Million
Previous $20.9 Million
483.08%
% of portfolio
1.72%
Previous 0.35%
Shares
11 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
95.2MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.61 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$553 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$341 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$287 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...